Molecular targeted therapy for hepatocellular carcinoma
10.3969/j.issn.1001-5256.2015.01.030
- VernacularTitle:肝细胞癌相关分子靶向治疗研究进展
- Author:
Yinan SHEN
1
;
Junhu LU
Author Information
1. Fifth Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China
- Publication Type:Research Article
- Keywords:
carcinoma, hepatocellular;
targeted therapy;
solafenib;
review
- From:
Journal of Clinical Hepatology
2015;31(1):130-
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is the most common malignancy in the liver, for which surgical operation remains the primary treatment. However, the surgical treatment is associated with low resection rate and high recurrence rate, which drive studies on the molecule mechanism of initiation, metastasis, and invasion of HCC, in order to develop more effective early diagnosis and treatment methods. By reviewing related literature, this article summarizes the major signaling pathways related to HCC, such as the PI3K/AKT/mTOR signaling pathway, RAS/RAF/MEK/ERK signaling pathway, and VEGF/VEGFR, PDGFR, and FGFR signaling pathway. New advances in the corresponding molecular targeted therapy for HCC are described, and the perspectives on future direction of relevant research are discussed.
